Tags

Type your tag names separated by a space and hit enter

Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
Int J Gynecol Pathol. 2007 Oct; 26(4):404-9.IJ

Abstract

A 2-tier system that classifies ovarian serous carcinoma (OSC) as low grade or high grade is gaining acceptance. Women with low-grade OSC generally have higher 5-year survival rates than do women with high-grade OSC. We examined the expression of various markers to further understand the molecular differences between low-grade and high-grade OSCs: the potential therapeutic targets or prognostic markers Her-2/neu, estrogen receptor, and progesterone receptor (PR); the metastasis-associated markers cyclin D1 (BCL1), E-cadherin, matrix metalloproteinase (MMP) 2, and MMP-9; and the cell proliferation-associated markers BCL1, Ki-67 antigen (Ki-67), and p53. For this immunohistochemical analysis, we used paraffin-embedded specimens from 47 patients with advanced-stage low-grade OSC and from 49 patients with advanced-stage high-grade OSC. Our results showed that low-grade tumors expressed significantly higher levels of estrogen receptor, PR, and E-cadherin than did high-grade tumors, suggesting the involvement of gonadal steroid hormones, especially in the pathogenesis of low-grade OSC; the PR positivity was also observed in the stromal component of these low-grade tumors. On the other hand, high-grade tumors trended toward increased expression of MMP-9, BCL1, p53, and Ki-67, and robust MMP-9 positivity was observed in the stromal component of these high-grade tumors. These differences may lead to the development of different therapeutic strategies for women with either the low-grade or the high-grade form of OSC.

Authors+Show Affiliations

Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. kkwong@mdanderson.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17885490

Citation

Wong, Kwong-Kwok, et al. "Significantly Greater Expression of ER, PR, and ECAD in Advanced-stage Low-grade Ovarian Serous Carcinoma as Revealed By Immunohistochemical Analysis." International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists, vol. 26, no. 4, 2007, pp. 404-9.
Wong KK, Lu KH, Malpica A, et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol. 2007;26(4):404-9.
Wong, K. K., Lu, K. H., Malpica, A., Bodurka, D. C., Shvartsman, H. S., Schmandt, R. E., Thornton, A. D., Deavers, M. T., Silva, E. G., & Gershenson, D. M. (2007). Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists, 26(4), 404-9.
Wong KK, et al. Significantly Greater Expression of ER, PR, and ECAD in Advanced-stage Low-grade Ovarian Serous Carcinoma as Revealed By Immunohistochemical Analysis. Int J Gynecol Pathol. 2007;26(4):404-9. PubMed PMID: 17885490.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. AU - Wong,Kwong-Kwok, AU - Lu,Karen H, AU - Malpica,Anais, AU - Bodurka,Diane C, AU - Shvartsman,Hyun S, AU - Schmandt,Rosemarie E, AU - Thornton,Angela D, AU - Deavers,Michael T, AU - Silva,Elvio G, AU - Gershenson,David M, PY - 2007/9/22/pubmed PY - 2007/11/14/medline PY - 2007/9/22/entrez SP - 404 EP - 9 JF - International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists JO - Int J Gynecol Pathol VL - 26 IS - 4 N2 - A 2-tier system that classifies ovarian serous carcinoma (OSC) as low grade or high grade is gaining acceptance. Women with low-grade OSC generally have higher 5-year survival rates than do women with high-grade OSC. We examined the expression of various markers to further understand the molecular differences between low-grade and high-grade OSCs: the potential therapeutic targets or prognostic markers Her-2/neu, estrogen receptor, and progesterone receptor (PR); the metastasis-associated markers cyclin D1 (BCL1), E-cadherin, matrix metalloproteinase (MMP) 2, and MMP-9; and the cell proliferation-associated markers BCL1, Ki-67 antigen (Ki-67), and p53. For this immunohistochemical analysis, we used paraffin-embedded specimens from 47 patients with advanced-stage low-grade OSC and from 49 patients with advanced-stage high-grade OSC. Our results showed that low-grade tumors expressed significantly higher levels of estrogen receptor, PR, and E-cadherin than did high-grade tumors, suggesting the involvement of gonadal steroid hormones, especially in the pathogenesis of low-grade OSC; the PR positivity was also observed in the stromal component of these low-grade tumors. On the other hand, high-grade tumors trended toward increased expression of MMP-9, BCL1, p53, and Ki-67, and robust MMP-9 positivity was observed in the stromal component of these high-grade tumors. These differences may lead to the development of different therapeutic strategies for women with either the low-grade or the high-grade form of OSC. SN - 0277-1691 UR - https://www.unboundmedicine.com/medline/citation/17885490/Significantly_greater_expression_of_ER_PR_and_ECAD_in_advanced_stage_low_grade_ovarian_serous_carcinoma_as_revealed_by_immunohistochemical_analysis_ L2 - https://doi.org/10.1097/pgp.0b013e31803025cd DB - PRIME DP - Unbound Medicine ER -